TABLE 2.
System organ classes (SOCs) for adverse events of different groups.
| SOC | Trastuzumab | Trastuzumab + Lapatinib | Trastuzumab + Neratinib | Trastuzumab + Tucatinib |
|---|---|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 89 | 2 | 2 | 2 |
| Investigations | 63 | 0 | 2 | 6 |
| Cardiac disorders | 53 | 0 | 0 | 0 |
| Infections and infestations | 30 | 2 | 1 | 6 |
| General disorders and administration site conditions | 27 | 2 | 4 | 3 |
| Respiratory, thoracic and mediastinal disorders | 27 | 0 | 2 | 2 |
| Skin and subcutaneous tissue disorders | 25 | 12 | 3 | 7 |
| Nervous system disorders | 23 | 3 | 4 | 9 |
| Injury, poisoning and procedural complications | 22 | 1 | 5 | 2 |
| Blood and lymphatic system disorders | 19 | 0 | 2 | 2 |
| Hepatobiliary disorders | 17 | 0 | 1 | 5 |
| Gastrointestinal disorders | 16 | 7 | 6 | 7 |
| Reproductive system and breast disorders | 14 | 0 | 0 | 0 |
| Surgical and medical procedures | 14 | 1 | 0 | 1 |
| Vascular disorders | 14 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | 11 | 0 | 0 | 0 |
| Eye disorders | 9 | 0 | 1 | 1 |
| Congenital, familial and genetic disorders | 6 | 0 | 0 | 1 |
| Metabolism and nutrition disorders | 5 | 1 | 3 | 0 |
| Immune system disorders | 2 | 0 | 0 | 0 |
| Renal and urinary disorders | 2 | 0 | 1 | 0 |
| Endocrine disorders | 1 | 0 | 0 | 2 |
| Pregnancy, puerperium and perinatal conditions | 1 | 0 | 0 | 0 |
| Psychiatric disorders | 1 | 0 | 1 | 2 |
| Product issues | 0 | 1 | 0 | 0 |
| Social circumstances | 0 | 0 | 0 | 1 |